Changes to the Code
H.R. 5435 · Stop CMV Act of 2025 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 300b–10 Advisory Committee on Heritable Disorders in Newborns and Children
+29 −27Shown
3 changes the bill asks for here, 3 carried out
- Carried out:
in paragraph (7) by striking
and
after the semicolon;
- Carried out:
by redesignating paragraph (8) as paragraph (9); and
- Carried out:
by inserting after paragraph (7) the following:
(8) carry out activities under section 1116A; and.
§ 300b–10(b)–(c)
Start of § 300b–10 to (b)(5) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b)(6) | (6) | (6) | ||
| develop a model decision-matrix for newborn screening expansion, including an evaluation of the potential public health impact, including the cost of such expansion, and periodically update the recommended uniform screening panel, as appropriate, based on such decision-matrix; | develop a model decision-matrix for newborn screening expansion, including an evaluation of the potential public health impact, including the cost of such expansion, and periodically update the recommended uniform screening panel, as appropriate, based on such decision-matrix; | |||
| (b)(7) | (7) | (7) | ||
| consider ways to ensure that all States attain the capacity to screen for the conditions described in paragraph (3), and include in such consideration the results of grant funding under section 300b–8 of this title; | consider ways to ensure that all States attain the capacity to screen for the conditions described in paragraph (3), and include in such consideration the results of grant funding under section 300b–8 of this title; | |||
| (b)(8) | (8) [inserted: ] | |||
| [inserted: carry out activities under section 1116A; and] | ||||
| (b)(9) | [inserted: (9)] | |||
| provide such recommendations, advice or information as may be necessary to enhance, expand or improve the ability of the Secretary to reduce the mortality or morbidity from heritable disorders, which may include recommendations, advice, or information dealing with— | provide such recommendations, advice or information as may be necessary to enhance, expand or improve the ability of the Secretary to reduce the mortality or morbidity from heritable disorders, which may include recommendations, advice, or information dealing with— | |||
| (b)(9)(A) | (A) | (A) | ||
| follow-up activities, including those necessary to achieve best practices in rapid diagnosis and appropriate treatment in the short-term, and those that ascertain long-term case management outcomes and appropriate access to related services; | follow-up activities, including those necessary to achieve best practices in rapid diagnosis and appropriate treatment in the short-term, and those that ascertain long-term case management outcomes and appropriate access to related services; | |||
| (b)(9)(B) | (B) | (B) | ||
| implementation, monitoring, and evaluation of newborn screening activities, including diagnosis, screening, follow-up, and treatment activities; | implementation, monitoring, and evaluation of newborn screening activities, including diagnosis, screening, follow-up, and treatment activities; | |||
| (b)(9)(C) | (C) | (C) | ||
| diagnostic and other technology used in screening; | diagnostic and other technology used in screening; | |||
| (b)(9)(D) | (D) | (D) | ||
| the availability and reporting of testing for conditions for which there is no existing treatment, including information on cost and incidence; | the availability and reporting of testing for conditions for which there is no existing treatment, including information on cost and incidence; | |||
| (b)(9)(E) | (E) | (E) | ||
| conditions not included in the recommended uniform screening panel that are treatable with Food and Drug Administration-approved products or other safe and effective treatments, as determined by scientific evidence and peer review; | conditions not included in the recommended uniform screening panel that are treatable with Food and Drug Administration-approved products or other safe and effective treatments, as determined by scientific evidence and peer review; | |||
| (b)(9)(F) | (F) | (F) | ||
| minimum standards and related policies and procedures used by State newborn screening programs, such as language and terminology used by State newborn screening programs to include standardization of case definitions and names of disorders for which newborn screening tests are performed; | minimum standards and related policies and procedures used by State newborn screening programs, such as language and terminology used by State newborn screening programs to include standardization of case definitions and names of disorders for which newborn screening tests are performed; | |||
| (b)(9)(G) | (G) | (G) | ||
| quality assurance, oversight, and evaluation of State newborn screening programs, including ensuring that tests and technologies used by each State meet established standards for detecting and reporting positive screening results; | quality assurance, oversight, and evaluation of State newborn screening programs, including ensuring that tests and technologies used by each State meet established standards for detecting and reporting positive screening results; | |||
| (b)(9)(H) | (H) | (H) | ||
| public and provider awareness and education; | public and provider awareness and education; | |||
| (b)(9)(I) | (I) | (I) | ||
| the cost and effectiveness of newborn screening and medical evaluation systems and intervention programs conducted by State-based programs; | the cost and effectiveness of newborn screening and medical evaluation systems and intervention programs conducted by State-based programs; | |||
| (b)(9)(J) | (J) | (J) | ||
| identification of the causes of, public health impacts of, and risk factors for heritable disorders; | identification of the causes of, public health impacts of, and risk factors for heritable disorders; | |||
| (b)(9)(K) | (K) | (K) | ||
| coordination of surveillance activities, including standardized data collection and reporting, harmonization of laboratory definitions for heritable disorders and testing results, and confirmatory testing and verification of positive results, in order to assess and enhance monitoring of newborn diseases; and | coordination of surveillance activities, including standardized data collection and reporting, harmonization of laboratory definitions for heritable disorders and testing results, and confirmatory testing and verification of positive results, in order to assess and enhance monitoring of newborn diseases; and | |||
| (b)(9)(L) | (L) | (L) | ||
| the timeliness of collection, delivery, receipt, and screening of specimens to be tested for heritable disorders in newborns in order to ensure rapid diagnosis and followup. | the timeliness of collection, delivery, receipt, and screening of specimens to be tested for heritable disorders in newborns in order to ensure rapid diagnosis and followup. | |||
| (c) | (c) Membership | (c) Membership | ||
| (c)(1) | (1) In general | (1) In general | ||
| The Secretary shall appoint not to exceed 15 members to the Advisory Committee. In appointing such members, the Secretary shall ensure that the total membership of the Advisory Committee is an odd number. | The Secretary shall appoint not to exceed 15 members to the Advisory Committee. In appointing such members, the Secretary shall ensure that the total membership of the Advisory Committee is an odd number. | |||
Rest of § 300b–10 unchanged